

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

Anti-4E-BP1, phospho (Thr37 / Thr46) Monoclonal Antibody

RRID:AB_560835

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2855, RRID:AB_560835

Antibody Information

URL: http://antibodyregistry.org/AB_560835

Proper Citation: Cell Signaling Technology Cat# 2855, RRID:AB_560835

Target Antigen: 4E-BP1, phospho (Thr37 / Thr46)

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-P, IF-IC, FC-FP
Consolidation on 10/2016: AB_560837, AB_10140942.

Antibody Name: Anti-4E-BP1, phospho (Thr37 / Thr46) Monoclonal Antibody

Description: This recombinant monoclonal targets 4E-BP1, phospho (Thr37 / Thr46)

Target Organism: monkey, rat, mouse, human

Clone ID: 236B4

Antibody ID: AB_560835

Vendor: Cell Signaling Technology

Catalog Number: 2855

Alternative Catalog Numbers: 2855P, 2855S, 2855L

Record Creation Time: 20260909T050735+0000

Record Last Update: 20260912T060128+0000

Ratings and Alerts

No rating or validation information has been found for Anti-4E-BP1, phospho (Thr37 / Thr46) Monoclonal Antibody.

No alerts have been found for Anti-4E-BP1, phospho (Thr37 / Thr46) Monoclonal Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 299 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Mao Y, et al. (2026) B cell deficiency limits exercise capacity by remodeling liver glutamate metabolism. *Cell*, 189(11), 3254.

Beale AD, et al. (2026) A cellular basis for the mammalian nocturnal-diurnal switch. *Science (New York, N.Y.)*, 391(6788), eady2822.

Ishikawa KI, et al. (2026) Suppression of ATM kinase signaling accelerates cellular senescence. *Stem cell reports*, 21(7), 102956.

Li G, et al. (2026) Non-enzymatic ABHD6 interacts with Akt-FoxO1 axis to regulate selective hepatic insulin resistance. *bioRxiv : the preprint server for biology*.

Chen YL, et al. (2026) Endometrial stromal cell-derived TMAO sustains decidualization to prevent recurrent spontaneous abortion. *Cell metabolism*.

Matsuura K, et al. (2026) Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. *Cell reports*, 45(7), 117630.

Grunfeld AM, et al. (2026) Amyloid-bodies in the evolution of malignancies. *PloS one*, 21(7), e0353464.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. *Cell chemical biology*, 33(1), 59.

Wehle DT, et al. (2026) Dissociation of the mTOR Protein Interaction Network Following Neuronal Activation Is Altered by Shank3 Mutation. *Journal of neurochemistry*, 170(1), e70353.

Fieblinger T, et al. (2026) Repurposing drugs for treating the neurobehavioral manifestations of PTEN hamartoma tumor syndrome. *iScience*, 29(4), 115428.

Li G, et al. (2026) Elucidation of mechanisms underlying the therapeutic effects of cordycepin on pulmonary hypertension, with a focus on cell senescence and gut microbiota. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 194, 118923.

Brady MR, et al. (2026) Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma. *Cancer research*, 86(5), 1166.

Xie C, et al. (2026) Lysosome-localized IRTKS condensates promote mTORC1 activity leading to MASLD and HCC. *Cell reports*, 45(2), 116893.

Tan M, et al. (2026) A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways. *bioRxiv : the preprint server for biology*.

Zhao Y, et al. (2026) Combined Photothermal and mTOR-Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple-Negative Breast Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(10), e13711.

Lara Castillo NA, et al. (2026) Exercise beneficially reshapes fasted rat skeletal muscle involving the combined action of β -hydroxybutyrate and palmitoleic acid. *American journal of physiology. Cell physiology*, 330(4), C1006.

He T, et al. (2026) β -Ketoglutarate couples cellular metabolism to developmental growth via hydroxylation-dependent degradation of Yorkie. *Cell reports*, 45(2), 116922.

Zink A, et al. (2026) Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy. *Cell*, 189(6), 1656.

Nakano H, et al. (2026) Maternal hyperglycemia disrupts cardiomyocyte maturation via aberrant nucleotide metabolism and suppression of AMPK signaling. *Cell reports*, 45(5), 117321.

Lin Y, et al. (2026) Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies. *eLife*, 15.